MDT: Leadership change

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On May 18, 2026, Medtronic plc (“Medtronic” or the “Company”) announced that Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio, and that Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026. Mr. Wall will remain an employee of the Company until September 1, 2026, to assist with the transition. Mr. Wall is entitled to and will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers as described in Medtronic’s 2025 Proxy Statement filed with the Securities and Exchange Commission on August 25, 2025. Item 9.01. Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Medtronic plc Date: May 18, 2026 By /s/ Michelle Quinn Michelle Quinn Executive Vice President, General Counsel